ClinicalTrials.gg
CompletedNCT05682326ASCEND-PUpdated Nov 10, 2025Results posted

Anemia Studies in CKD: Erythropoiesis Via a Novel PHI Daprodustat - Pediatric (ASCEND-P)

A Phase 3 interventional study of Daprodustat in Anaemia, sponsored by GlaxoSmithKline. Completed at 4 sites in 2 countries. Open to participants aged 3 Months to 17 Years. Per ClinicalTrials.gov, last updated 2025-11-10.

Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
4
Allocation
Not applicable
Ages
3 Months to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 30 studies testing GSK1278863 in Anemia — 1 open to participants now, 1 under way, 1 of them phase 3. GSK1278863 · Anemia.

Enrollment
30th of 30
4 · median 76
Started
2023
with 1 other
Phase 3
9 of 30
1 open now
Registered
28th of 30
by date
Lead sponsor
28 of 30
GlaxoSmithKline

Among the 30 studies testing GSK1278863 in Anemia, this one is the 30th largest by enrollment, is one of 2 that started in 2023, is one of 9 in phase 3, and was the 28th registered.

Anemia

1,810 studies on the registry are indexed under Anemia; 215 are open to participants now.

Browse Anemia studies →

Open to participants now

1 of the 30 studies testing GSK1278863 in Anemia is open now. Recruiting first, the newest first:

About GSK1278863

GSK1278863: first FDA approval 2023 (JESDUVROQ). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 122 Anemia studies recruiting now, 67 (55%) set no upper age limit and 37 (30%) stop at 75 or younger; 34 take children under 18; 23 take healthy volunteers.

This study: 3 Months to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 30 studies testing GSK1278863 in Anemia, or all of them as a file.
02

Study summary

This is an international, multicenter trial, evaluating pharmacokinetics (PK) (4 weeks), safety (52 weeks), and hemoglobin (Hgb) response (52 weeks) to daprodustat in children and adolescent participants with anemia associated with chronic kidney disease (CKD) incorporating 2 independent sub-trials (Non dialysis [ND] and Dialysis [D]). This study will enroll participants with anemia associated with CKD, in 2 distinct sub-populations differing only by their CKD stage and dialysis requirement (ND: CKD stage 3 to 5 not yet receiving dialysis and D: CKD stage 5d undergoing peritoneal dialysis [PD] or hemodialysis [HD]).

The maximum duration of the study will be approximately 60 weeks, including Screening period (up to 4 weeks), treatment period (52 weeks), and follow-up period (4 weeks).

Outcome measures are identical for the ND and D sub-trials, but will be separately assessed in each sub- trials, overall and within each age subgroups (12 to less than [\<] 18 years, 6 to \<12 years, 2 to \<6 years, and 3 months to \<2 years). Except for PK and dose change, which is within each age group only.

03

Conditions studied

  • Anaemia

Keywords

  • Daprodustat
  • ASCEND-P
  • Anemia
  • Chronic kidney disease
  • Erythropoiesis stimulating agent
  • Dialysis
  • Non-dialysis
  • 214066
  • 212914
04

Who can participate

Ages eligible
3 Months to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant must be 3 months to less than (\<)18 years of age.
  • Anemia associated with CKD stage 3, 4, 5 (not on dialysis) or who have dialysis-dependent CKD, defined as 7.0 to 11.0 g/dL (if not using erythropoiesis stimulating agents [ESAs]) or Hgb 9.5 to 12.0 g/dL if using ESAs.
  • Written or assent as appropriate.

Exclusion criteria

Exclusion Criteria:

  • Kidney transplant recipient with a functioning allograft.
  • Scheduled for elective kidney transplantation within 3 months.
  • Transferrin saturation (TSAT) \< 20 percent (%), or Ferritin \<25 nanogram (ng)/milliliter (mL).
  • History of bone marrow aplasia or pure red cell aplasia.
  • Active hemolysis.
  • Other causes of anemia.
  • Active gastrointestinal bleeding within the last 4 weeks.
  • Active or previous within the last 2 years.
  • Acute or chronic infection requiring antimicrobial therapy.
  • History of significant thrombotic or thromboembolic events within the last 8 weeks.
  • Heart failure (HF) (NYHA) Class IV
  • Uncontrolled hypertension.
  • (ALT) >2× (ULN), >1.5× ULN (unless bilirubin is fractionated and direct bilirubin \<35%), and cirrhosis or current unstable liver or biliary disease.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
4 participants (actual)

Study arms

  • Experimental
    Daprodustat

    All participants will receive daprodustat for up to 52 weeks.

    Drug: Daprodustat

Interventions

  • Daprodustat will be administered up to Week 52.

06

What researchers measure

Primary outcomes

  1. Number of Participants With Any Adverse Events (AEs) and Serious Adverse Events (SAEs)

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. SAEs are defined as any untoward medical occurrence that, at any dose: results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; or other situations as per medical and scientific judgement of the Investigator.

    Time frame: Up to 56 weeks

  2. Number of Participants With Adverse Event of Special Interests (AESIs)

    AESIs are AEs of scientific interest specific to the drug class as per investigator assessment. AESI included: Death, Myocardial Infarction (MI), stroke, Heart Failure (HF), thromboembolic events, thrombosis of vascular access, Thrombosis and/or tissue ischemia secondary to excessive erythropoiesis, New diagnosis of hypertension or worsening of existing hypertension, Cancer related mortality and tumor progression and recurrence, Esophageal and gastric erosions. Number of participants with any AESIs have been presented.

    Time frame: Up to 56 weeks

  3. Number of Participants With AEs Leading to Study Intervention Discontinuation

    All AEs leading to study intervention discontinuation were collected. Number of participants with any AEs leading to study intervention discontinuation have been presented

    Time frame: Up to 52 weeks

Secondary outcomes

  1. Change From Baseline in Hematology Parameter: Hematocrit

    Blood samples were collected to analyze the hematology parameter: hematocrit. Baseline value was defined as the last non-missing value prior to the start date and time of the study medication (Day 1). Change from Baseline was calculated as the value at indicated time point minus the value at Baseline.

    Time frame: Baseline (Day 1), at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52

  2. Change From Baseline in Hematology Parameter: Reticulocytes/Erythrocytes

    Blood samples were collected to analyze the hematology parameter: Reticulocytes/Erythrocytes. Baseline value was defined as the last non-missing value prior to the start date and time of the study medication (Day 1). Change from Baseline was calculated as the value at indicated time point minus the value at Baseline.

    Time frame: Baseline (Day 1), at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52

  3. Change From Baseline in Hematology Parameter: Erythrocytes

    Blood samples were collected to analyze the hematology parameter: Erythrocytes. Baseline value was defined as the last non-missing value prior to the start date and time of the study medication (Day 1). Change from Baseline was calculated as the value at indicated time point minus the value at Baseline.

    Time frame: Baseline (Day 1), at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52

  4. Change From Baseline in Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Leukocytes and Platelet Count

    Blood samples were collected to analyze the hematology parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Leukocytes and Platelet count. Baseline value was defined as the last non-missing value prior to the start date and time of the study medication (Day 1). Change from Baseline was calculated as the value at indicated time point minus the value at Baseline.

    Time frame: Baseline (Day 1), at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52

  5. Change From Baseline in Hematology Parameter: Erythrocytes Mean Corpuscular Volume

    Blood samples were collected to analyze the hematology parameter: Erythrocytes Mean Corpuscular Volume. Baseline value was defined as the last non-missing value prior to the start date and time of the study medication (Day 1). Change from Baseline was calculated as the value at indicated time point minus the value at Baseline.

    Time frame: Baseline (Day 1), at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52

  6. Change From Baseline in Hematology Parameter: Erythrocytes Mean Corpuscular Hemoglobin

    Blood samples were collected to analyze the hematology parameter: Erythrocytes Mean Corpuscular Hemoglobin. Baseline value was defined as the last non-missing value prior to the start date and time of the study medication (Day 1). Change from Baseline was calculated as the value at indicated time point minus the value at Baseline.

    Time frame: Baseline (Day 1), at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52

  7. Change From Baseline in Clinical Chemistry Parameters: Calcium, Potassium, Sodium, Blood Urea Nitrogen (BUN)

    Blood samples were collected to analyze the clinical chemistry parameters: Calcium, Potassium, Sodium and BUN. Baseline value was defined as the last non-missing value prior to the start date and time of the study medication (Day 1). Change from Baseline was calculated as the value at indicated time point minus the value at Baseline.

    Time frame: Baseline (Day 1), at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52

  8. Change From Baseline in Clinical Chemistry Parameter: Creatinine

    Blood samples were collected to analyze the clinical chemistry parameter: Creatinine. Baseline value was defined as the last non-missing value prior to the start date and time of the study medication (Day 1). Change from Baseline was calculated as the value at indicated time point minus the value at Baseline.

    Time frame: Baseline (Day 1), at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52

  9. Change From Baseline in Clinical Chemistry Parameters: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP) and Aspartate Aminotransferase (AST)

    Blood samples were collected to analyze the clinical chemistry parameters: ALT, ALP and AST. Baseline value was defined as the last non-missing value prior to the start date and time of the study medication (Day 1). Change from Baseline was calculated as the value at indicated time point minus the value at Baseline.

    Time frame: Baseline (Day 1), at Weeks 4, 8, 12, 24, 32, 36, 40, 48, and 52

  10. Change From Baseline in Clinical Chemistry Parameters: Bilirubin and Direct Bilirubin

    Blood samples were collected to analyze the clinical chemistry parameters: Bilirubin and Direct Bilirubin. Baseline value was defined as the last non-missing value prior to the start date and time of the study medication (Day 1). Change from Baseline was calculated as the value at indicated time point minus the value at Baseline.

    Time frame: Baseline (Day 1), at Weeks 4, 8, 12, 24, 32, 36, 40, 48, and 52

  11. Change From Baseline in Clinical Chemistry Parameter: Protein

    Blood samples were collected to analyze the clinical chemistry parameter: Protein. Baseline value was defined as the last non-missing value prior to the start date and time of the study medication (Day 1). Change from Baseline was calculated as the value at indicated time point minus the value at Baseline.

    Time frame: Baseline (Day 1), at Weeks 4, 8, 12, 24, 32, 36, 40, 48, and 52

  12. Change From Baseline in Clinical Chemistry Parameter: Ferritin

    Blood samples were collected to analyze the clinical chemistry parameter: Ferritin. Baseline value was defined as the last non-missing value prior to the start date and time of the study medication (Day 1). Change from Baseline was calculated as the value at indicated time point minus the value at Baseline.

    Time frame: Baseline (Day 1), at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52

  13. Change From Baseline in Clinical Chemistry Parameter: Transferrin Saturation

    Blood samples were collected to analyze the clinical chemistry parameter: Transferrin saturation. Transferrin saturation is measured as a percentage, it is the ratio of serum iron and total iron-binding capacity, multiplied by 100. Baseline value was defined as the last non-missing value prior to the start date and time of the study medication (Day 1). Change from Baseline was calculated as the value at indicated time point minus the value at Baseline.

    Time frame: Baseline (Day 1), at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52

  14. Change From Baseline in Clinical Chemistry Parameter: Estimated Glomerular Filtration Rate

    Blood samples were collected to analyze the clinical chemistry parameter: Estimated Glomerular Filtration Rate. Baseline value was defined as the last non-missing value prior to the start date and time of the study medication (Day 1). Change from Baseline was calculated as the value at indicated time point minus the value at Baseline.

    Time frame: Baseline (Day 1), at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52

  15. Change From Baseline in Hematology Parameter: Prothrombin International Normalized Ratio

    Blood samples were collected to analyze the hematology parameter: Prothrombin International Normalized Ratio. It is used to assess the clotting ability of blood. Baseline value was defined as the last non-missing value prior to the start date and time of the study medication (Day 1). Change from Baseline was calculated as the value at indicated time point minus the value at Baseline.

    Time frame: Baseline (Day 1), at Weeks 4, 8, 12, 24, 32, 36, 40, 48, and 52

  16. Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)

    Systolic and diastolic blood pressure (BP) were assessed using an appropriate size cuff preceded by at least 5 minutes of rest for the participant in a quiet setting without distractions (e.g., television, cell phones). Baseline value was defined as the last non-missing value prior to the start date and time of the study medication (Day 1). Change from Baseline was calculated as the value at indicated time point minus the value at Baseline.

    Time frame: Baseline (Day 1), at Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52

  17. Change From Baseline in Heart Rate (HR)

    Heart rate (HR) were assessed using an appropriate size cuff preceded by at least 5 minutes of rest for the participant in a quiet setting without distractions (e.g., television, cell phones). Baseline value was defined as the last non-missing value prior to the start date and time of the study medication (Day 1). Change from Baseline was calculated as the value at indicated time point minus the value at Baseline.

    Time frame: Baseline (Day 1), at Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52

  18. Change From Baseline in Weight

    Weight readings in kilogram (kg) were collected. Baseline value was defined as the last non-missing value prior to the start date and time of the study medication (Day 1). Change from Baseline was calculated as the value at indicated time point minus the value at Baseline.

    Time frame: Baseline (Day 1), at Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52

  19. Change From Baseline in Height

    Height readings in centimeters (cm) were collected. Baseline value was defined as the last non-missing value prior to the start date and time of the study medication (Day 1). Change from Baseline was calculated as the value at indicated time point minus the value at Baseline.

    Time frame: Baseline (Day 1), at Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52

  20. Absolute Values of Hemoglobin (Hgb)

    Blood samples were collected from all participants for measurement of Hgb values in grams per deciliter (g/dL). Baseline value was defined as the last non-missing value prior to the start date and time of the study medication (Day 1). Hgb results of participants with intercurrent events were excluded from the summary.

    Time frame: Baseline (Day 1), at Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52

  21. Change From Baseline in Hemoglobin (Hgb)

    Blood samples were collected from all participants for measurement of Hgb values in g/dL. Baseline value was defined as the last non-missing value prior to the start date and time of the study medication (Day 1). Change from Baseline was calculated as the value at indicated time point minus the value at Baseline. Hgb results of participants with intercurrent events were excluded from the summary.

    Time frame: Baseline (Day 1), at Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52

  22. Number of Participants With Hgb Values Above, Below and Within the Target Range (10 to 12 g/dL)

    Number of participants with Hgb values above, below, and within the target range (10 to 12 g/dL) were assessed. Baseline assessment was defined as the last non-missing value prior to the start date and time of the study drug (Day 1). Hgb results of participants with intercurrent events were excluded from the summary.

    Time frame: Baseline (Day 1), at Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52

  23. Change in Daprodustat Dose From Starting Dose at Each Study Time Point

    Daprodustat dose was adjusted, if required, one step at a time in the range of 1 to 24 mg, to maintain the target range for Hgb between 10 to 12 g/dL. Dose change values of daprodustat from starting dose at each study time point were calculated as dose level at indicated time point minus starting dose at Day 1 (Baseline).

    Time frame: Day 1 (Baseline), at Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, and 48

  24. Number of Participants With 0 to 10, or Greater Than (>) 10 Dose Adjustments

    Number of participants who required daprodustat dose adjustments form the starting dose were assessed. Data were categorized for number of participants who required no dose change (0 times) to 10 times and \>10 times dose adjustments during the study.

    Time frame: Up to Week 52

  25. Daprodustat Dose at Each Study Time Point

    Mean and standard deviation of daprodustat dose received by participants at each study time point has been presented.

    Time frame: Baseline (Day 1), at Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, and 48

  26. Maximum Plasma Concentration (Cmax) of Daprodustat

    Blood samples were collected for the plasma concentrations of daprodustat from which pharmacokinetic (PK) parameters were determined. Mean and standard deviation of daprodustat Cmax at steady state obtained via modeling in each sub-trial (requiring Dialysis and not yet requiring Dialysis).

    Time frame: Day 1: 1, 2 and 6 hours Post-dose; Week 2: Pre-dose and 1, 2 and 6 hours Post-dose

  27. Area Under the Curve (AUC) at Steady State of Daprodustat

    Blood samples were collected for the plasma concentrations of daprodustat from which PK parameters were determined. Mean and standard deviation of daprodustat AUC at steady state obtained via modeling in each sub-trial (requiring Dialysis and not yet requiring Dialysis).

    Time frame: Day 1: 1, 2 and 6 hours Post-dose; Week 2: Pre-dose and 1, 2 and 6 hours Post-dose

  28. Plasma Concentrations of Daprodustat and Metabolites at Pre-dose (Ctrough)

    Blood samples were collected for the plasma concentrations of daprodustat and metabolites from which PK parameters were determined. Mean and standard deviation of raw daprodustat and metabolites (GSK2391220, GSK2487818, GSK2506102, GSK2506104, GSK2531398 and GSK2531401) at steady state at pre-dose obtained via modeling in each sub-trial (requiring Dialysis and not yet requiring Dialysis).

    Time frame: Pre-dose on Week 2

07

Results

Posted Nov 10, 2025

Participant flow

Participants were enrolled into two sub-trials based on dialysis status under a master protocol. The non-dialysis (ND) sub-trial enrolled pediatric participants with anemia associated with chronic kidney disease (CKD) not yet requiring dialysis in non-US countries. The dialysis (D) sub-trial enrolled pediatric participants with anemia associated with CKD requiring dialysis in non-US countries. Recruitment was conducted separately for each sub-trial.

Participant flow — Overall Study
MilestoneParticipants Requiring Dialysis (D)Participants Not Yet Requiring Dialysis (ND)
Started22
Completed12
Not completed10
Withdrew: Withdrawal by subject10

Outcome measures

PrimaryNumber of Participants With Any Adverse Events (AEs) and Serious Adverse Events (SAEs)

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. SAEs are defined as any untoward medical occurrence that, at any dose: results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; or other situations as per medical and scientific judgement of the Investigator.

Time frame:
Up to 56 weeks
Reported as:
Count of participants · Participants
Number of Participants With Any Adverse Events (AEs) and Serious Adverse Events (SAEs)
ParticipantsParticipants Requiring Dialysis (D)Participants Not Yet Requiring Dialysis (ND)
Any AEs22
Any SAEs10
PrimaryNumber of Participants With Adverse Event of Special Interests (AESIs)

AESIs are AEs of scientific interest specific to the drug class as per investigator assessment. AESI included: Death, Myocardial Infarction (MI), stroke, Heart Failure (HF), thromboembolic events, thrombosis of vascular access, Thrombosis and/or tissue ischemia secondary to excessive erythropoiesis, New diagnosis of hypertension or worsening of existing hypertension, Cancer related mortality and tumor progression and recurrence, Esophageal and gastric erosions. Number of participants with any AESIs have been presented.

Time frame:
Up to 56 weeks
Reported as:
Count of participants · Participants
Number of Participants With Adverse Event of Special Interests (AESIs)
ParticipantsParticipants Requiring Dialysis (D)Participants Not Yet Requiring Dialysis (ND)
Number of Participants With Adverse Event of Special Interests (AESIs)00
PrimaryNumber of Participants With AEs Leading to Study Intervention Discontinuation

All AEs leading to study intervention discontinuation were collected. Number of participants with any AEs leading to study intervention discontinuation have been presented

Time frame:
Up to 52 weeks
Reported as:
Count of participants · Participants
Number of Participants With AEs Leading to Study Intervention Discontinuation
ParticipantsParticipants Requiring Dialysis (D)Participants Not Yet Requiring Dialysis (ND)
Number of Participants With AEs Leading to Study Intervention Discontinuation00
SecondaryChange From Baseline in Hematology Parameter: Hematocrit

Blood samples were collected to analyze the hematology parameter: hematocrit. Baseline value was defined as the last non-missing value prior to the start date and time of the study medication (Day 1). Change from Baseline was calculated as the value at indicated time point minus the value at Baseline.

Time frame:
Baseline (Day 1), at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52
Reported as:
Mean · Percentage of red blood cells in blood
Change From Baseline in Hematology Parameter: Hematocrit
Percentage of red blood cells in bloodParticipants Requiring Dialysis (D)Participants Not Yet Requiring Dialysis (ND)
Week 40.0160 ± NA0.0030 ± 0.03818
Week 80.0530 ± NA0.0025 ± 0.03889
Week 12-0.0280 ± NA0.0135 ± 0.01485
Week 16-0.0200 ± NA-0.0185 ± 0.03889
Week 200.0000 ± NA-0.0005 ± 0.01909
Week 240.0050 ± NA0.0060 ± 0.02687
Week 280.0340 ± NA-0.0050 ± 0.03536
Week 320.0350 ± NA0.0370 ± NA
Week 360.0070 ± NA0.0095 ± 0.02333
Week 40-0.0220 ± NA0.0270 ± 0.04667
Week 44-0.0020 ± NA-0.0060 ± 0.03677
Week 48—0.0035 ± 0.01909
Week 52-0.0320 ± NA0.0020 ± 0.01980
SecondaryChange From Baseline in Hematology Parameter: Reticulocytes/Erythrocytes

Blood samples were collected to analyze the hematology parameter: Reticulocytes/Erythrocytes. Baseline value was defined as the last non-missing value prior to the start date and time of the study medication (Day 1). Change from Baseline was calculated as the value at indicated time point minus the value at Baseline.

Time frame:
Baseline (Day 1), at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52
Reported as:
Mean · Ratio of Reticulocytes to Erythrocytes
Change From Baseline in Hematology Parameter: Reticulocytes/Erythrocytes
Ratio of Reticulocytes to ErythrocytesParticipants Requiring Dialysis (D)Participants Not Yet Requiring Dialysis (ND)
Week 40.0080 ± NA-0.0039 ± 0.00686
Week 8-0.0020 ± NA0.0031 ± 0.00134
Week 120.0060 ± NA-0.0012 ± 0.00594
Week 160.0100 ± NA-0.0024 ± 0.00481
Week 200.0110 ± NA0.0001 ± 0.00693
Week 240.0060 ± NA-0.0020 ± 0.00700
Week 280.0040 ± NA0.0007 ± 0.00467
Week 320.0030 ± NA-0.0037 ± NA
Week 360.0020 ± NA0.0010 ± 0.00573
Week 400.0070 ± NA-0.0020 ± 0.00849
Week 440.0100 ± NA0.0010 ± 0.00714
Week 48—0.0026 ± 0.00771
Week 520.0040 ± NA0.0018 ± 0.00453
SecondaryChange From Baseline in Hematology Parameter: Erythrocytes

Blood samples were collected to analyze the hematology parameter: Erythrocytes. Baseline value was defined as the last non-missing value prior to the start date and time of the study medication (Day 1). Change from Baseline was calculated as the value at indicated time point minus the value at Baseline.

Time frame:
Baseline (Day 1), at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52
Reported as:
Mean · Trillion cells per Liter (10^12 cells/L)
Change From Baseline in Hematology Parameter: Erythrocytes
Trillion cells per Liter (10^12 cells/L)Participants Requiring Dialysis (D)Participants Not Yet Requiring Dialysis (ND)
Week 40.130 ± NA0.060 ± 0.4243
Week 80.480 ± NA0.045 ± 0.4313
Week 12-0.350 ± NA0.060 ± 0.2546
Week 16-0.350 ± NA-0.280 ± 0.5374
Week 200.010 ± NA-0.050 ± 0.2970
Week 240.030 ± NA0.025 ± 0.3889
Week 280.250 ± NA-0.095 ± 0.4879
Week 320.350 ± NA0.350 ± NA
Week 360.030 ± NA0.050 ± 0.3111
Week 40-0.330 ± NA0.310 ± 0.4808
Week 44-0.260 ± NA-0.080 ± 0.5515
Week 48—-0.025 ± 0.2758
Week 52-0.490 ± NA-0.050 ± 0.2687
SecondaryChange From Baseline in Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Leukocytes and Platelet Count

Blood samples were collected to analyze the hematology parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Leukocytes and Platelet count. Baseline value was defined as the last non-missing value prior to the start date and time of the study medication (Day 1). Change from Baseline was calculated as the value at indicated time point minus the value at Baseline.

Time frame:
Baseline (Day 1), at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52
Reported as:
Mean · Giga cells per Liter (10^9 cells/L)
Change From Baseline in Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Leukocytes and Platelet Count
Giga cells per Liter (10^9 cells/L)Participants Requiring Dialysis (D)Participants Not Yet Requiring Dialysis (ND)
Basophils: Week 40.0120 ± NA0.0007 ± 0.01509
Basophils: Week 8-0.0177 ± NA0.0087 ± 0.01232
Basophils: Week 12-0.0011 ± NA0.0093 ± 0.01312
Basophils: Week 16-0.0062 ± NA-0.0038 ± 0.02292
Basophils: Week 200.0085 ± NA0.0162 ± 0.02295
Basophils: Week 24-0.0044 ± NA0.0066 ± 0.02353
Basophils: Week 280.0182 ± NA0.0003 ± 0.01458
Basophils: Week 32-0.0209 ± NA0.0314 ± NA
Basophils: Week 36-0.0091 ± NA0.0051 ± 0.02139
Basophils: Week 40-0.0020 ± NA0.0063 ± 0.00522
Basophils: Week 44-0.0091 ± NA0.0001 ± 0.00017
Basophils: Week 48—0.0059 ± 0.00833
Basophils: Week 520.0012 ± NA-0.0001 ± 0.00008
Eosinophils: Week 40.0146 ± NA0.4193 ± 0.63542
Eosinophils: Week 8-0.0962 ± NA0.2385 ± 0.30899
Eosinophils: Week 12-0.0072 ± NA0.2547 ± 0.11973
Eosinophils: Week 160.0239 ± NA0.1184 ± 0.15326
Eosinophils: Week 20-0.0037 ± NA0.0989 ± 0.13988
Eosinophils: Week 240.0203 ± NA0.0698 ± 0.18356
Eosinophils: Week 28-0.0578 ± NA0.0238 ± 0.07607
Eosinophils: Week 32-0.1571 ± NA0.2913 ± NA
Eosinophils: Week 36-0.0775 ± NA0.0395 ± 0.14069
Eosinophils: Week 40-0.1208 ± NA0.0357 ± 0.07683
Eosinophils: Week 44-0.0522 ± NA0.0395 ± 0.02754
Eosinophils: Week 48—0.1645 ± 0.10537
Eosinophils: Week 52-0.0628 ± NA0.0390 ± 0.00136
Lymphocytes: Week 40.2799 ± NA-0.2606 ± 0.01499
Lymphocytes: Week 80.4370 ± NA-0.4114 ± 0.49299
Lymphocytes: Week 12-0.2165 ± NA-0.2552 ± 0.57253
Lymphocytes: Week 16-0.2907 ± NA-0.2009 ± 0.40885
Lymphocytes: Week 200.1325 ± NA-0.3649 ± 0.58710
Lymphocytes: Week 24-0.1535 ± NA-0.3050 ± 0.58684
Lymphocytes: Week 280.0289 ± NA-0.2517 ± 0.50673
Lymphocytes: Week 32-1.1501 ± NA0.6357 ± NA
Lymphocytes: Week 360.0581 ± NA-0.4619 ± 1.00143
Lymphocytes: Week 40-0.2134 ± NA-0.4961 ± 0.05108
Lymphocytes: Week 440.5638 ± NA-0.4021 ± 0.50620
Lymphocytes: Week 48—-0.1701 ± 0.33923
Lymphocytes: Week 520.4700 ± NA-0.5256 ± 0.60026
Monocytes: Week 40.0408 ± NA-0.0318 ± 0.03079
Monocytes: Week 80.1094 ± NA0.0230 ± 0.15981
Monocytes: Week 12-0.0258 ± NA0.0536 ± 0.01924
Monocytes: Week 16-0.0289 ± NA0.0148 ± 0.00684
Monocytes: Week 200.0132 ± NA-0.0307 ± 0.11217
Monocytes: Week 24-0.0404 ± NA-0.0310 ± 0.04098
Monocytes: Week 280.0169 ± NA-0.0314 ± 0.06868
Monocytes: Week 32-0.2902 ± NA0.0410 ± NA
Monocytes: Week 36-0.0410 ± NA-0.0596 ± 0.01360
Monocytes: Week 40-0.0708 ± NA0.0884 ± 0.20985
Monocytes: Week 440.0601 ± NA-0.0110 ± 0.02690
Monocytes: Week 48—0.0492 ± 0.04132
Monocytes: Week 520.0164 ± NA-0.0112 ± 0.01583
Neutrophils: Week 4-0.1973 ± NA-0.1626 ± 0.16602
Neutrophils: Week 8-3.5926 ± NA0.4712 ± 1.43005
Neutrophils: Week 12-0.1094 ± NA0.4876 ± 0.20136
Neutrophils: Week 16-1.7681 ± NA1.3315 ± 1.27070
Neutrophils: Week 20-0.8705 ± NA-0.0296 ± 0.38241
Neutrophils: Week 24-1.2919 ± NA0.2346 ± 0.30353
Neutrophils: Week 281.6839 ± NA-0.1160 ± 0.33096
Neutrophils: Week 32-5.3517 ± NA1.1306 ± NA
Neutrophils: Week 361.2095 ± NA0.4269 ± 0.70272
Neutrophils: Week 40-0.2730 ± NA1.0158 ± 0.85667
Neutrophils: Week 440.5974 ± NA0.0185 ± 0.11095
Neutrophils: Week 48—0.3055 ± 0.11948
Neutrophils: Week 52-0.0248 ± NA0.6728 ± 0.91533
Leukocytes: Week 40.150 ± NA-0.045 ± 0.7849
Leukocytes: Week 8-3.160 ± NA0.315 ± 2.4254
Leukocytes: Week 12-0.360 ± NA0.510 ± 0.5798
Leukocytes: Week 16-2.070 ± NA1.240 ± 0.6505
Leukocytes: Week 20-0.720 ± NA-0.315 ± 1.2516
Leukocytes: Week 24-1.470 ± NA-0.060 ± 1.1879
Leukocytes: Week 281.690 ± NA-0.385 ± 1.0112
Leukocytes: Week 32-6.970 ± NA2.130 ± NA
Leukocytes: Week 361.140 ± NA-0.070 ± 1.8809
Leukocytes: Week 40-0.680 ± NA0.605 ± 0.9970
Leukocytes: Week 441.160 ± NA-0.390 ± 0.7212
Leukocytes: Week 48—0.310 ± 0.4384
Leukocytes: Week 520.400 ± NA0.170 ± 0.3253
Platelet count: Week 416.0 ± NA-30.0 ± 26.87
Platelet count: Week 8-31.0 ± NA-41.5 ± 34.65
Platelet count: Week 12-11.0 ± NA-32.0 ± 39.60
Platelet count: Week 16-5.0 ± NA-47.0 ± 14.14
Platelet count: Week 205.0 ± NA-39.5 ± 27.58
Platelet count: Week 24-11.0 ± NA-10.0 ± 7.07
Platelet count: Week 2810.0 ± NA-14.5 ± 6.36
Platelet count: Week 326.0 ± NA1.0 ± NA
Platelet count: Week 36-4.0 ± NA-25.0 ± 0.00
Platelet count: Week 4023.0 ± NA-18.5 ± 27.58
Platelet count: Week 4428.0 ± NA-7.5 ± 37.48
Platelet count: Week 48—-36.0 ± 35.36
Platelet count: Week 5230.0 ± NA11.0 ± 65.05
SecondaryChange From Baseline in Hematology Parameter: Erythrocytes Mean Corpuscular Volume

Blood samples were collected to analyze the hematology parameter: Erythrocytes Mean Corpuscular Volume. Baseline value was defined as the last non-missing value prior to the start date and time of the study medication (Day 1). Change from Baseline was calculated as the value at indicated time point minus the value at Baseline.

Time frame:
Baseline (Day 1), at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52
Reported as:
Mean · Femtoliter (fL)
Change From Baseline in Hematology Parameter: Erythrocytes Mean Corpuscular Volume
Femtoliter (fL)Participants Requiring Dialysis (D)Participants Not Yet Requiring Dialysis (ND)
Week 41.00 ± NA-0.45 ± 0.919
Week 82.10 ± NA-0.35 ± 0.919
Week 121.00 ± NA2.00 ± 1.414
Week 163.10 ± NA1.15 ± 1.344
Week 20-0.20 ± NA0.85 ± 1.202
Week 240.60 ± NA0.95 ± 1.202
Week 282.60 ± NA0.70 ± 1.131
Week 320.80 ± NA1.90 ± NA
Week 361.00 ± NA1.25 ± 0.495
Week 402.10 ± NA0.35 ± 1.626
Week 445.60 ± NA0.20 ± 1.980
Week 48—1.35 ± 0.778
Week 523.40 ± NA1.45 ± 0.495
SecondaryChange From Baseline in Hematology Parameter: Erythrocytes Mean Corpuscular Hemoglobin

Blood samples were collected to analyze the hematology parameter: Erythrocytes Mean Corpuscular Hemoglobin. Baseline value was defined as the last non-missing value prior to the start date and time of the study medication (Day 1). Change from Baseline was calculated as the value at indicated time point minus the value at Baseline.

Time frame:
Baseline (Day 1), at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52
Reported as:
Mean · Picogram (pg)
Change From Baseline in Hematology Parameter: Erythrocytes Mean Corpuscular Hemoglobin
Picogram (pg)Participants Requiring Dialysis (D)Participants Not Yet Requiring Dialysis (ND)
Week 40.30 ± NA0.00 ± 0.849
Week 80.20 ± NA0.45 ± 0.071
Week 120.70 ± NA0.70 ± 0.141
Week 161.30 ± NA0.95 ± 0.212
Week 200.90 ± NA0.85 ± 0.212
Week 241.30 ± NA0.70 ± 0.000
Week 281.20 ± NA1.45 ± 0.212
Week 321.00 ± NA0.40 ± NA
Week 360.50 ± NA1.15 ± 0.636
Week 401.60 ± NA0.55 ± 0.212
Week 442.10 ± NA0.55 ± 1.061
Week 48—0.80 ± 0.566
Week 521.80 ± NA1.95 ± 1.626
SecondaryChange From Baseline in Clinical Chemistry Parameters: Calcium, Potassium, Sodium, Blood Urea Nitrogen (BUN)

Blood samples were collected to analyze the clinical chemistry parameters: Calcium, Potassium, Sodium and BUN. Baseline value was defined as the last non-missing value prior to the start date and time of the study medication (Day 1). Change from Baseline was calculated as the value at indicated time point minus the value at Baseline.

Time frame:
Baseline (Day 1), at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52
Reported as:
Mean · millimoles per liter (mmol/L)
Change From Baseline in Clinical Chemistry Parameters: Calcium, Potassium, Sodium, Blood Urea Nitrogen (BUN)
millimoles per liter (mmol/L)Participants Requiring Dialysis (D)Participants Not Yet Requiring Dialysis (ND)
Calcium: Week 40.0749 ± NA-0.1123 ± 0.05293
Calcium: Week 8-0.1248 ± NA-0.1248 ± 0.10585
Calcium: Week 12-0.0499 ± NA-0.1372 ± 0.12350
Calcium: Week 160.0000 ± NA-0.1372 ± 0.12350
Calcium: Week 200.0250 ± NA-0.0873 ± 0.08821
Calcium: Week 240.0250 ± NA-0.0873 ± 0.15878
Calcium: Week 28-0.0499 ± NA-0.1871 ± 0.08821
Calcium: Week 320.0250 ± NA0.0000 ± NA
Calcium: Week 360.1248 ± NA-0.1372 ± 0.12350
Calcium: Week 400.0000 ± NA-0.0624 ± 0.05293
Calcium: Week 440.1248 ± NA-0.1248 ± 0.07057
Calcium: Week 48—-0.1123 ± 0.08821
Calcium: Week 520.0998 ± NA-0.1747 ± 0.14114
Potassium: Week 40.40 ± NA-0.35 ± 0.354
Potassium: Week 80.30 ± NA-0.40 ± 0.000
Potassium: Week 120.40 ± NA-0.30 ± 0.283
Potassium: Week 160.10 ± NA-0.45 ± 0.212
Potassium: Week 200.30 ± NA-0.10 ± 0.424
Potassium: Week 240.20 ± NA-0.05 ± 0.495
Potassium: Week 280.30 ± NA-0.55 ± 0.354
Potassium: Week 320.30 ± NA-0.30 ± NA
Potassium: Week 360.20 ± NA-0.35 ± 0.071
Potassium: Week 400.40 ± NA-0.55 ± 0.354
Potassium: Week 440.20 ± NA-0.40 ± 0.424
Potassium: Week 48—-0.25 ± 0.495
Potassium: Week 520.50 ± NA-0.20 ± 0.283
Sodium: Week 40.0 ± NA0.5 ± 3.54
Sodium: Week 80.0 ± NA-0.5 ± 0.71
Sodium: Week 12-1.0 ± NA0.0 ± 0.00
Sodium: Week 160.0 ± NA0.5 ± 3.54
Sodium: Week 201.0 ± NA-2.0 ± 2.83
Sodium: Week 240.0 ± NA0.5 ± 2.12
Sodium: Week 28-2.0 ± NA-0.5 ± 3.54
Sodium: Week 320.0 ± NA-3.0 ± NA
Sodium: Week 360.0 ± NA-0.5 ± 2.12
Sodium: Week 400.0 ± NA-2.5 ± 3.54
Sodium: Week 441.0 ± NA-0.5 ± 4.95
Sodium: Week 48—-1.0 ± 2.83
Sodium: Week 52-1.0 ± NA0.5 ± 2.12
BUN: Week 40.9996 ± NA0.0893 ± 3.40790
BUN: Week 8-0.2142 ± NA2.1242 ± 4.06424
BUN: Week 121.7136 ± NA0.6962 ± 2.54961
BUN: Week 161.3923 ± NA0.1964 ± 4.77106
BUN: Week 200.7854 ± NA0.8390 ± 0.83304
BUN: Week 240.6069 ± NA0.0000 ± 3.02925
BUN: Week 283.6057 ± NA0.0893 ± 2.90303
BUN: Week 322.2134 ± NA1.4280 ± NA
BUN: Week 364.1055 ± NA0.4820 ± 1.33792
BUN: Week 40-0.6426 ± NA4.1948 ± 7.19446
BUN: Week 442.2848 ± NA1.1603 ± 2.90303
BUN: Week 48—0.4463 ± 2.90303
BUN: Week 521.9278 ± NA1.1424 ± 4.94777
SecondaryChange From Baseline in Clinical Chemistry Parameter: Creatinine

Blood samples were collected to analyze the clinical chemistry parameter: Creatinine. Baseline value was defined as the last non-missing value prior to the start date and time of the study medication (Day 1). Change from Baseline was calculated as the value at indicated time point minus the value at Baseline.

Time frame:
Baseline (Day 1), at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52
Reported as:
Mean · micromoles per Liter (µmol/L)
Change From Baseline in Clinical Chemistry Parameter: Creatinine
micromoles per Liter (µmol/L)Participants Requiring Dialysis (D)Participants Not Yet Requiring Dialysis (ND)
Week 421.2160 ± NA-3.0940 ± 5.62574
Week 8139.6720 ± NA-0.4420 ± 9.37624
Week 12-1.7680 ± NA3.9780 ± 10.62640
Week 164.4200 ± NA14.5860 ± 19.37755
Week 20-22.1000 ± NA12.3760 ± 6.25082
Week 24-5.3040 ± NA24.3100 ± 26.87854
Week 2878.6760 ± NA13.7020 ± 13.12673
Week 3283.9800 ± NA48.6200 ± NA
Week 3695.4720 ± NA32.2660 ± 45.63101
Week 40100.7760 ± NA65.4160 ± 75.00989
Week 44115.8040 ± NA49.5040 ± 57.50758
Week 48—56.1340 ± 65.63365
Week 52151.1640 ± NA73.8140 ± 94.38744
SecondaryChange From Baseline in Clinical Chemistry Parameters: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP) and Aspartate Aminotransferase (AST)

Blood samples were collected to analyze the clinical chemistry parameters: ALT, ALP and AST. Baseline value was defined as the last non-missing value prior to the start date and time of the study medication (Day 1). Change from Baseline was calculated as the value at indicated time point minus the value at Baseline.

Time frame:
Baseline (Day 1), at Weeks 4, 8, 12, 24, 32, 36, 40, 48, and 52
Reported as:
Mean · International units per liter
Change From Baseline in Clinical Chemistry Parameters: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP) and Aspartate Aminotransferase (AST)
International units per literParticipants Requiring Dialysis (D)Participants Not Yet Requiring Dialysis (ND)
ALT: Week 42.0 ± NA-2.0 ± 0.00
ALT: Week 82.0 ± NA-2.5 ± 0.71
ALT: Week 122.0 ± NA-3.5 ± 0.71
ALT: Week 240.0 ± NA-3.5 ± 2.12
ALT: Week 321.0 ± NA-5.0 ± NA
ALT: Week 36-1.0 ± NA-1.0 ± 0.00
ALT: Week 40-2.0 ± NA-3.5 ± 2.12
ALT: Week 48—-0.5 ± 4.95
ALT: Week 520.0 ± NA-4.5 ± 0.71
ALP: Week 434.0 ± NA-29.0 ± NA
ALP: Week 813.0 ± NA77.0 ± NA
ALP: Week 1231.0 ± NA123.0 ± NA
ALP: Week 2436.0 ± NA23.0 ± NA
ALP: Week 3229.0 ± NA141.0 ± NA
ALP: Week 3614.0 ± NA113.0 ± NA
ALP: Week 402.0 ± NA100.0 ± NA
ALP: Week 48—35.0 ± NA
ALP: Week 522.0 ± NA46.0 ± NA
AST: Week 43.0 ± NA-1.0 ± 1.41
AST: Week 85.0 ± NA-1.0 ± 1.41
AST: Week 120.0 ± NA-4.0 ± 2.83
AST: Week 24-1.0 ± NA-5.5 ± 3.54
AST: Week 321.0 ± NA-4.0 ± NA
AST: Week 36-2.0 ± NA-2.5 ± 3.54
AST: Week 40-3.0 ± NA-4.0 ± 4.24
AST: Week 48—-4.5 ± 4.95
AST: Week 52-2.0 ± NA-6.0 ± 4.24
SecondaryChange From Baseline in Clinical Chemistry Parameters: Bilirubin and Direct Bilirubin

Blood samples were collected to analyze the clinical chemistry parameters: Bilirubin and Direct Bilirubin. Baseline value was defined as the last non-missing value prior to the start date and time of the study medication (Day 1). Change from Baseline was calculated as the value at indicated time point minus the value at Baseline.

Time frame:
Baseline (Day 1), at Weeks 4, 8, 12, 24, 32, 36, 40, 48, and 52
Reported as:
Mean · micromoles per Liter (µmol/L)
Change From Baseline in Clinical Chemistry Parameters: Bilirubin and Direct Bilirubin
micromoles per Liter (µmol/L)Participants Requiring Dialysis (D)Participants Not Yet Requiring Dialysis (ND)
Bilirubin: Week 40.0000 ± NA1.1115 ± 1.57190
Bilirubin: Week 80.0000 ± NA1.5390 ± 2.17647
Bilirubin: Week 120.0000 ± NA3.4200 ± 4.83661
Bilirubin: Week 24-1.7100 ± NA4.9590 ± 2.17647
Bilirubin: Week 320.0000 ± NA3.4200 ± NA
Bilirubin: Week 360.0000 ± NA1.9665 ± 0.36275
Bilirubin: Week 400.0000 ± NA3.5910 ± 0.24183
Bilirubin: Week 48—-0.3420 ± 0.48366
Bilirubin: Week 52-1.7100 ± NA1.6245 ± 2.29739
Direct Bilirubin: Week 40.0000 ± NA0.0000 ± 0.00000
Direct Bilirubin: Week 80.0000 ± NA0.1710 ± 0.24183
Direct Bilirubin: Week 120.0000 ± NA0.4275 ± 0.60458
Direct Bilirubin: Week 240.0000 ± NA0.4275 ± 0.60458
Direct Bilirubin: Week 320.0000 ± NA0.0000 ± NA
Direct Bilirubin: Week 360.0000 ± NA0.0855 ± 0.12092
Direct Bilirubin: Week 400.0000 ± NA0.0000 ± 0.00000
Direct Bilirubin: Week 48—0.0855 ± 0.12092
Direct Bilirubin: Week 520.0000 ± NA0.0855 ± 0.12092
SecondaryChange From Baseline in Clinical Chemistry Parameter: Protein

Blood samples were collected to analyze the clinical chemistry parameter: Protein. Baseline value was defined as the last non-missing value prior to the start date and time of the study medication (Day 1). Change from Baseline was calculated as the value at indicated time point minus the value at Baseline.

Time frame:
Baseline (Day 1), at Weeks 4, 8, 12, 24, 32, 36, 40, 48, and 52
Reported as:
Mean · Grams per liter
Change From Baseline in Clinical Chemistry Parameter: Protein
Grams per literParticipants Requiring Dialysis (D)Participants Not Yet Requiring Dialysis (ND)
Week 46.00 ± NA-2.30 ± 1.838
Week 85.00 ± NA-1.85 ± 1.202
Week 12-1.00 ± NA-2.65 ± 0.495
Week 242.00 ± NA-1.45 ± 2.051
Week 324.00 ± NA2.00 ± NA
Week 366.00 ± NA-1.65 ± 3.748
Week 403.00 ± NA2.25 ± 5.303
Week 48—0.10 ± 2.687
Week 523.00 ± NA-0.65 ± 2.333
SecondaryChange From Baseline in Clinical Chemistry Parameter: Ferritin

Blood samples were collected to analyze the clinical chemistry parameter: Ferritin. Baseline value was defined as the last non-missing value prior to the start date and time of the study medication (Day 1). Change from Baseline was calculated as the value at indicated time point minus the value at Baseline.

Time frame:
Baseline (Day 1), at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52
Reported as:
Mean · micrograms per liter (µg/L)
Change From Baseline in Clinical Chemistry Parameter: Ferritin
micrograms per liter (µg/L)Participants Requiring Dialysis (D)Participants Not Yet Requiring Dialysis (ND)
Week 4-32.00 ± NA-12.60 ± 20.365
Week 8167.00 ± NA-17.30 ± 12.304
Week 1228.00 ± NA-23.30 ± 19.375
Week 16-29.00 ± NA-24.95 ± 9.970
Week 20-35.00 ± NA-28.50 ± 13.435
Week 24-33.00 ± NA-26.95 ± 22.698
Week 28-36.00 ± NA-27.65 ± 25.951
Week 32-14.00 ± NA-22.00 ± NA
Week 3642.00 ± NA-31.00 ± 12.728
Week 4042.00 ± NA-9.60 ± 37.335
Week 4475.00 ± NA-3.00 ± 59.397
Week 48—-16.30 ± 50.487
Week 5239.00 ± NA-5.05 ± 56.498
SecondaryChange From Baseline in Clinical Chemistry Parameter: Transferrin Saturation

Blood samples were collected to analyze the clinical chemistry parameter: Transferrin saturation. Transferrin saturation is measured as a percentage, it is the ratio of serum iron and total iron-binding capacity, multiplied by 100. Baseline value was defined as the last non-missing value prior to the start date and time of the study medication (Day 1). Change from Baseline was calculated as the value at indicated time point minus the value at Baseline.

Time frame:
Baseline (Day 1), at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52
Reported as:
Mean · Percentage (%) of transferrin saturation
Change From Baseline in Clinical Chemistry Parameter: Transferrin Saturation
Percentage (%) of transferrin saturationParticipants Requiring Dialysis (D)Participants Not Yet Requiring Dialysis (ND)
Week 4-6.900 ± NA-14.990 ± 43.8548
Week 8-2.300 ± NA6.385 ± 7.6155
Week 126.500 ± NA-18.245 ± 68.9500
Week 16-0.900 ± NA-2.775 ± 4.5608
Week 20-3.600 ± NA-18.500 ± 55.8614
Week 24-7.770 ± NA-12.995 ± 55.1614
Week 28-6.900 ± NA-29.050 ± 56.4978
Week 32-8.100 ± NA-69.000 ± NA
Week 363.100 ± NA-31.620 ± 62.7628
Week 403.100 ± NA-32.230 ± 52.0006
Week 44-7.600 ± NA-27.305 ± 27.8529
Week 48—-25.715 ± 28.6873
Week 52-1.500 ± NA-7.520 ± 51.5905
SecondaryChange From Baseline in Clinical Chemistry Parameter: Estimated Glomerular Filtration Rate

Blood samples were collected to analyze the clinical chemistry parameter: Estimated Glomerular Filtration Rate. Baseline value was defined as the last non-missing value prior to the start date and time of the study medication (Day 1). Change from Baseline was calculated as the value at indicated time point minus the value at Baseline.

Time frame:
Baseline (Day 1), at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52
Reported as:
Mean · mL per minute per 1.73 square meter
Change From Baseline in Clinical Chemistry Parameter: Estimated Glomerular Filtration Rate
mL per minute per 1.73 square meterParticipants Requiring Dialysis (D)Participants Not Yet Requiring Dialysis (ND)
Week 4-0.380 ± NA0.615 ± 0.7990
Week 8-2.020 ± NA-0.310 ± 2.4042
Week 120.040 ± NA-1.095 ± 3.0335
Week 16-0.060 ± NA-1.530 ± 2.0365
Week 200.440 ± NA-1.740 ± 0.3253
Week 240.130 ± NA-2.655 ± 2.3405
Week 28-0.930 ± NA-1.200 ± 1.2445
Week 32-1.320 ± NA-4.650 ± NA
Week 36-1.460 ± NA-2.370 ± 5.1053
Week 40-1.580 ± NA-6.565 ± 4.3346
Week 44-1.770 ± NA-4.855 ± 4.0800
Week 48—-5.410 ± 4.4548
Week 52-2.260 ± NA-5.935 ± 6.6539
SecondaryChange From Baseline in Hematology Parameter: Prothrombin International Normalized Ratio

Blood samples were collected to analyze the hematology parameter: Prothrombin International Normalized Ratio. It is used to assess the clotting ability of blood. Baseline value was defined as the last non-missing value prior to the start date and time of the study medication (Day 1). Change from Baseline was calculated as the value at indicated time point minus the value at Baseline.

Time frame:
Baseline (Day 1), at Weeks 4, 8, 12, 24, 32, 36, 40, 48, and 52
Reported as:
Mean · Ratio
Change From Baseline in Hematology Parameter: Prothrombin International Normalized Ratio
RatioParticipants Requiring Dialysis (D)Participants Not Yet Requiring Dialysis (ND)
Week 4-0.010 ± NA-0.010 ± NA
Week 8-0.040 ± NA0.050 ± NA
Week 120.010 ± NA0.030 ± NA
Week 24-0.040 ± NA0.010 ± NA
Week 32-0.010 ± NA—
Week 360.010 ± NA-0.020 ± NA
Week 400.030 ± NA0.010 ± NA
Week 48—-0.010 ± NA
Week 520.030 ± NA0.040 ± NA
SecondaryChange From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)

Systolic and diastolic blood pressure (BP) were assessed using an appropriate size cuff preceded by at least 5 minutes of rest for the participant in a quiet setting without distractions (e.g., television, cell phones). Baseline value was defined as the last non-missing value prior to the start date and time of the study medication (Day 1). Change from Baseline was calculated as the value at indicated time point minus the value at Baseline.

Time frame:
Baseline (Day 1), at Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52
Reported as:
Mean · millimeters of mercury (mmHg)
Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)
millimeters of mercury (mmHg)Participants Requiring Dialysis (D)Participants Not Yet Requiring Dialysis (ND)
SBP: Week 211.5 ± 9.19-8.0 ± 11.31
SBP: Week 49.0 ± NA3.5 ± 7.78
SBP: Week 86.0 ± NA-0.5 ± 16.26
SBP: Week 120.0 ± NA-9.5 ± 7.78
SBP: Week 162.0 ± NA-8.5 ± 2.12
SBP: Week 208.0 ± NA-7.5 ± 9.19
SBP: Week 2425.0 ± NA-7.0 ± 2.83
SBP: Week 2817.0 ± NA0.0 ± 19.80
SBP: Week 3220.0 ± NA20.0 ± NA
SBP: Week 3616.0 ± NA2.5 ± 14.85
SBP: Week 4010.0 ± NA-1.0 ± 28.28
SBP: Week 447.0 ± NA-5.5 ± 0.71
SBP: Week 48—4.0 ± 29.70
SBP: Week 524.0 ± NA0.0 ± 16.97
DBP: Week 23.5 ± 2.12-7.5 ± 3.54
DBP: Week 419.0 ± NA2.5 ± 14.85
DBP: Week 88.0 ± NA-3.0 ± 2.83
DBP: Week 12-4.0 ± NA-1.0 ± 1.41
DBP: Week 165.0 ± NA-8.0 ± 0.00
DBP: Week 204.0 ± NA-10.0 ± 9.90
DBP: Week 2416.0 ± NA-4.5 ± 10.61
DBP: Week 286.0 ± NA4.0 ± 8.49
DBP: Week 328.0 ± NA7.0 ± NA
DBP: Week 3611.0 ± NA5.0 ± 4.24
DBP: Week 402.0 ± NA0.0 ± 5.66
DBP: Week 4411.0 ± NA4.5 ± 0.71
DBP: Week 48—-2.0 ± 0.00
DBP: Week 521.0 ± NA-6.0 ± 1.41
SecondaryChange From Baseline in Heart Rate (HR)

Heart rate (HR) were assessed using an appropriate size cuff preceded by at least 5 minutes of rest for the participant in a quiet setting without distractions (e.g., television, cell phones). Baseline value was defined as the last non-missing value prior to the start date and time of the study medication (Day 1). Change from Baseline was calculated as the value at indicated time point minus the value at Baseline.

Time frame:
Baseline (Day 1), at Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52
Reported as:
Mean · beats per minute (bpm)
Change From Baseline in Heart Rate (HR)
beats per minute (bpm)Participants Requiring Dialysis (D)Participants Not Yet Requiring Dialysis (ND)
Week 2-12.5 ± 9.19-9.0 ± 4.24
Week 42.0 ± NA-2.0 ± 18.38
Week 815.0 ± NA-8.0 ± 28.28
Week 125.0 ± NA-11.0 ± 43.84
Week 16-10.0 ± NA-12.0 ± 14.14
Week 200.0 ± NA4.0 ± 14.14
Week 248.0 ± NA5.5 ± 6.36
Week 2814.0 ± NA3.0 ± 5.66
Week 3211.0 ± NA-12.0 ± NA
Week 361.00 ± NA3.5 ± 7.78
Week 40-1.0 ± NA30.0 ± NA
Week 4412.0 ± NA-3.5 ± 12.02
Week 48—-17.5 ± 14.85
Week 52-3.0 ± NA3.0 ± 1.41
SecondaryChange From Baseline in Weight

Weight readings in kilogram (kg) were collected. Baseline value was defined as the last non-missing value prior to the start date and time of the study medication (Day 1). Change from Baseline was calculated as the value at indicated time point minus the value at Baseline.

Time frame:
Baseline (Day 1), at Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52
Reported as:
Mean · kilograms (Kg)
Change From Baseline in Weight
kilograms (Kg)Participants Requiring Dialysis (D)Participants Not Yet Requiring Dialysis (ND)
Week 2-1.00 ± 0.141-0.70 ± 0.566
Week 4-1.80 ± NA-0.25 ± 1.485
Week 8-2.40 ± NA0.40 ± 0.141
Week 121.20 ± NA1.00 ± 0.566
Week 16-0.50 ± NA0.60 ± 0.283
Week 202.200.70 ± 0.849
Week 242.00 ± NA0.45 ± 0.212
Week 281.70 ± NA0.80 ± 0.990
Week 321.00 ± NA1.90 ± NA
Week 360.20 ± NA0.95 ± 1.768
Week 400.80 ± NA0.95 ± 1.061
Week 441.50 ± NA1.85 ± 0.495
Week 48—2.90 ± 0.000
Week 521.30 ± NA2.70 ± 0.000
SecondaryChange From Baseline in Height

Height readings in centimeters (cm) were collected. Baseline value was defined as the last non-missing value prior to the start date and time of the study medication (Day 1). Change from Baseline was calculated as the value at indicated time point minus the value at Baseline.

Time frame:
Baseline (Day 1), at Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52
Reported as:
Mean · centimeters (cm)
Change From Baseline in Height
centimeters (cm)Participants Requiring Dialysis (D)Participants Not Yet Requiring Dialysis (ND)
Week 2-1.50 ± 2.1210.85 ± 1.202
Week 40.00 ± NA0.95 ± 0.495
Week 80.00 ± NA1.20 ± 0.707
Week 120.00 ± NA2.65 ± 0.071
Week 160.10 ± NA1.85 ± 1.485
Week 200.30 ± NA3.35 ± 0.495
Week 240.30 ± NA3.70 ± 0.707
Week 281.00 ± NA4.60 ± 0.141
Week 320.80 ± NA5.30 ± NA
Week 360.50 ± NA5.00 ± 1.131
Week 400.20 ± NA4.50 ± 2.546
Week 440.20 ± NA5.65 ± 2.192
Week 48—5.65 ± 2.192
Week 52-0.70 ± NA6.25 ± 2.333
SecondaryAbsolute Values of Hemoglobin (Hgb)

Blood samples were collected from all participants for measurement of Hgb values in grams per deciliter (g/dL). Baseline value was defined as the last non-missing value prior to the start date and time of the study medication (Day 1). Hgb results of participants with intercurrent events were excluded from the summary.

Time frame:
Baseline (Day 1), at Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52
Reported as:
Mean · grams per deciliter
Absolute Values of Hemoglobin (Hgb)
grams per deciliterParticipants Requiring Dialysis (D)Participants Not Yet Requiring Dialysis (ND)
Baseline (Day 1)11.00 ± 0.42411.35 ± 0.919
Week 210.85 ± 1.06111.90 ± 0.990
Week 411.80 ± NA11.50 ± 0.566
Week 8—11.65 ± 0.212
Week 12—11.80 ± 0.283
Week 16—10.95 ± 0.495
Week 20—11.55 ± 0.212
Week 24—11.70 ± 0.141
Week 28—11.65 ± 0.354
Week 32—11.80 ± NA
Week 36—11.95 ± 0.354
Week 40—12.10 ± NA
Week 44—11.20 ± NA
Week 48—11.90 ± NA
Week 52—12.60 ± NA
SecondaryChange From Baseline in Hemoglobin (Hgb)

Blood samples were collected from all participants for measurement of Hgb values in g/dL. Baseline value was defined as the last non-missing value prior to the start date and time of the study medication (Day 1). Change from Baseline was calculated as the value at indicated time point minus the value at Baseline. Hgb results of participants with intercurrent events were excluded from the summary.

Time frame:
Baseline (Day 1), at Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52
Reported as:
Mean · grams per Liter
Change From Baseline in Hemoglobin (Hgb)
grams per LiterParticipants Requiring Dialysis (D)Participants Not Yet Requiring Dialysis (ND)
Week 2-0.15 ± 0.6360.55 ± 0.071
Week 40.5 ± NA0.15 ± 1.485
Week 8—0.30 ± 1.131
Week 12—0.45 ± 0.636
Week 16—-0.40 ± 1.414
Week 20—0.20 ± 0.707
Week 24—0.35 ± 1.061
Week 28—0.30 ± 1.273
Week 32—1.10 ± NA
Week 36—0.60 ± 0.566
Week 40—0.10 ± NA
Week 44—-0.80 ± NA
Week 48—-0.10 ± NA
Week 52—0.60 ± NA
SecondaryNumber of Participants With Hgb Values Above, Below and Within the Target Range (10 to 12 g/dL)

Number of participants with Hgb values above, below, and within the target range (10 to 12 g/dL) were assessed. Baseline assessment was defined as the last non-missing value prior to the start date and time of the study drug (Day 1). Hgb results of participants with intercurrent events were excluded from the summary.

Time frame:
Baseline (Day 1), at Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52
Reported as:
Count of participants · Participants
Number of Participants With Hgb Values Above, Below and Within the Target Range (10 to 12 g/dL)
ParticipantsParticipants Requiring Dialysis (D)Participants Not Yet Requiring Dialysis (ND)
Baseline (Day 1) — Above Target Range00
Baseline (Day 1) — Within Target Range22
Baseline (Day 1) — Below Target Range00
Week 2 — Above Target Range01
Week 2 — Within Target Range21
Week 2 — Below Target Range00
Week 4 — Above Target Range00
Week 4 — Within Target Range12
Week 4 — Below Target Range00
Week 8 — Above Target Range—0
Week 8 — Within Target Range—2
Week 8 — Below Target Range—0
Week 12 — Above Target Range—0
Week 12 — Within Target Range—2
Week 12 — Below Target Range—0
Week 16 — Above Target Range—0
Week 16 — Within Target Range—2
Week 16 — Below Target Range—0
Week 20 — Above Target Range—0
Week 20 — Within Target Range—2
Week 20 — Below Target Range—0
Week 24 — Above Target Range—0
Week 24 — Within Target Range—2
Week 24 — Below Target Range—0
Week 28 — Above Target Range—0
Week 28 — Within Target Range—2
Week 28 — Below Target Range—0
Week 32 — Above Target Range—0
Week 32 — Within Target Range—1
Week 32 — Below Target Range—0
Week 36 — Above Target Range—1
Week 36 — Within Target Range—1
Week 36 — Below Target Range—0
Week 40 — Above Target Range—1
Week 40 — Within Target Range—0
Week 40 — Below Target Range—0
Week 44 — Above Target Range—0
Week 44 — Within Target Range—1
Week 44 — Below Target Range—0
Week 48 — Above Target Range—0
Week 48 — Within Target Range—1
Week 48 — Below Target Range—0
Week 52 — Above Target Range—1
Week 52 — Within Target Range—0
Week 52 — Below Target Range—0
SecondaryChange in Daprodustat Dose From Starting Dose at Each Study Time Point

Daprodustat dose was adjusted, if required, one step at a time in the range of 1 to 24 mg, to maintain the target range for Hgb between 10 to 12 g/dL. Dose change values of daprodustat from starting dose at each study time point were calculated as dose level at indicated time point minus starting dose at Day 1 (Baseline).

Time frame:
Day 1 (Baseline), at Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, and 48
Reported as:
Mean · milligrams
Change in Daprodustat Dose From Starting Dose at Each Study Time Point
milligramsParticipants Requiring Dialysis (D)Participants Not Yet Requiring Dialysis (ND)
Week 20 ± 0-1 ± 1.41
Week 40 ± NA-0.5 ± 0.71
Week 8-6 ± NA-0.5 ± 0.71
Week 12-2 ± NA-0.5 ± 0.71
Week 160 ± NA-0.5 ± 0.71
Week 200 ± NA-0.5 ± 0.71
Week 240 ± NA-0.5 ± 0.71
Week 28-2 ± NA-0.5 ± 0.71
Week 32-6 ± NA0 ± NA
Week 36-4 ± NA-1 ± 1.41
Week 40-4 ± NA-2 ± 0
Week 44-4 ± NA-1 ± 0
Week 48—-1 ± NA
SecondaryNumber of Participants With 0 to 10, or Greater Than (>) 10 Dose Adjustments

Number of participants who required daprodustat dose adjustments form the starting dose were assessed. Data were categorized for number of participants who required no dose change (0 times) to 10 times and \>10 times dose adjustments during the study.

Time frame:
Up to Week 52
Reported as:
Count of participants · Participants
Number of Participants With 0 to 10, or Greater Than (>) 10 Dose Adjustments
ParticipantsParticipants Requiring Dialysis (D)Participants Not Yet Requiring Dialysis (ND)
No dose change (0 time)10
1 time00
2 times01
3 times00
4 times00
5 times00
6 times11
7 times00
8 times00
9 times00
10 times00
>10 times00
SecondaryDaprodustat Dose at Each Study Time Point

Mean and standard deviation of daprodustat dose received by participants at each study time point has been presented.

Time frame:
Baseline (Day 1), at Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, and 48
Reported as:
Mean · milligrams
Daprodustat Dose at Each Study Time Point
milligramsParticipants Requiring Dialysis (D)Participants Not Yet Requiring Dialysis (ND)
Baseline (Day 1)6.0 ± 0.002.0 ± 0.00
Week 26.0 ± 0.001.0 ± 1.41
Week 46.0 ± NA1.5 ± 0.71
Week 80.0 ± NA1.5 ± 0.71
Week 124.0 ± NA1.5 ± 0.71
Week 166.0 ± NA1.5 ± 0.71
Week 206.0 ± NA1.5 ± 0.71
Week 246.00 ± NA1.5 ± 0.71
Week 284.0 ± NA1.5 ± 0.71
Week 320.0 ± NA2.0 ± NA
Week 362.0 ± NA1.0 ± 1.41
Week 402.0 ± NA0.0 ± 0.00
Week 442.0 ± NA1.0 ± 0.00
Week 48—1.0 ± NA
SecondaryMaximum Plasma Concentration (Cmax) of Daprodustat

Blood samples were collected for the plasma concentrations of daprodustat from which pharmacokinetic (PK) parameters were determined. Mean and standard deviation of daprodustat Cmax at steady state obtained via modeling in each sub-trial (requiring Dialysis and not yet requiring Dialysis).

Time frame:
Day 1: 1, 2 and 6 hours Post-dose; Week 2: Pre-dose and 1, 2 and 6 hours Post-dose
Reported as:
Mean · Nanograms per milliliters (ng/mL)
Maximum Plasma Concentration (Cmax) of Daprodustat
Nanograms per milliliters (ng/mL)Participants Requiring Dialysis (D)Participants Not Yet Requiring Dialysis (ND)
Maximum Plasma Concentration (Cmax) of Daprodustat115.047 ± 3.85419.447 ± 10.770
SecondaryArea Under the Curve (AUC) at Steady State of Daprodustat

Blood samples were collected for the plasma concentrations of daprodustat from which PK parameters were determined. Mean and standard deviation of daprodustat AUC at steady state obtained via modeling in each sub-trial (requiring Dialysis and not yet requiring Dialysis).

Time frame:
Day 1: 1, 2 and 6 hours Post-dose; Week 2: Pre-dose and 1, 2 and 6 hours Post-dose
Reported as:
Mean · Hours*nanogram per milliliter (h*ng/mL)
Area Under the Curve (AUC) at Steady State of Daprodustat
Hours*nanogram per milliliter (h*ng/mL)Participants Requiring Dialysis (D)Participants Not Yet Requiring Dialysis (ND)
Area Under the Curve (AUC) at Steady State of Daprodustat185.379 ± 8.66156.634 ± 6.009
SecondaryPlasma Concentrations of Daprodustat and Metabolites at Pre-dose (Ctrough)

Blood samples were collected for the plasma concentrations of daprodustat and metabolites from which PK parameters were determined. Mean and standard deviation of raw daprodustat and metabolites (GSK2391220, GSK2487818, GSK2506102, GSK2506104, GSK2531398 and GSK2531401) at steady state at pre-dose obtained via modeling in each sub-trial (requiring Dialysis and not yet requiring Dialysis).

Time frame:
Pre-dose on Week 2
Reported as:
Mean · Nanograms per milliliters (ng/mL)
Plasma Concentrations of Daprodustat and Metabolites at Pre-dose (Ctrough)
Nanograms per milliliters (ng/mL)Participants Requiring Dialysis (D)Participants Not Yet Requiring Dialysis (ND)
Daprodustat0.4995 ± 0.3698NA ± NA
GSK23912206.540 ± 2.206NA ± NA
GSK24878180.869 ± 0.137NA ± NA
GSK25061023.040 ± 0.424NA ± NA
GSK250610410.55 ± 3.180.143 ± NA
GSK25313982.490 ± 0.184NA ± NA
GSK253140111.25 ± 1.480.127 ± NA

Adverse events

Collected over All-cause mortality, serious adverse events (SAEs) and non-serious adverse events (Non-SAEs) were collected up to 56 weeks.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Participants Requiring Dialysis (D)0/2 (0%)1/2 (50%)2/2 (100%)
Participants Not Yet Requiring Dialysis (ND)0/2 (0%)0/2 (0%)2/2 (100%)
Most frequent serious events
Most frequent serious events
EventParticipants Requiring Dialysis (D)Participants Not Yet Requiring Dialysis (ND)
Congenital uterine anomalyCongenital, familial and genetic disorders1/20/2
Retroperitoneal haematomaGastrointestinal disorders1/20/2
HypertensionVascular disorders1/20/2
Most frequent other events
Most frequent other events
EventParticipants Requiring Dialysis (D)Participants Not Yet Requiring Dialysis (ND)
NasopharyngitisInfections and infestations0/21/2
Foot fractureInjury, poisoning and procedural complications0/21/2
COVID-19Infections and infestations0/21/2
HypertensionVascular disorders1/20/2
Serum ferritin increasedInvestigations1/20/2

Baseline characteristics

Age, Customized
Age, Customized(Participants)Participants Requiring Dialysis (D)Participants Not Yet Requiring Dialysis (ND)Total
12 to <18 years224
Sex: Female, Male
Sex: Female, Male(Participants)Participants Requiring Dialysis (D)Participants Not Yet Requiring Dialysis (ND)Total
Female202
Male022
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Participants Requiring Dialysis (D)Participants Not Yet Requiring Dialysis (ND)Total
All Other Races224
08

Study locations

4 sites
  • GSK Investigational Site
    Aichi, 466-8650, Japan
  • GSK Investigational Site
    Saitama, 330-8777, Japan
  • GSK Investigational Site
    Tokyo, 162-8666, Japan
  • GSK Investigational Site
    Yangsan, 50612, South Korea
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers may request access to anonymized individual patient-level data (IPD) and related study documents of the eligible studies via the Data Sharing Portal. Details on GSK's data sharing criteria can be found at: https://www.gsk.com/en-gb/innovation/trials/data-transparency/

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or terminated asset(s) across all indications.

Access criteria: Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension may be granted, when justified, for up to 6 months.

Data sharing details ↗ · www.gsk.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2023 to primary completion in Oct 2024, 13 months.

Results were first posted in Nov 2025, 1 year after primary completion.

Of 98 industry-sponsored phase 3 interventional studies under Anemia, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 49. This study's 13 months is below that.

Counting every sponsor, half of 149 studies reached it within 30 months; a quarter within 17 and three quarters within 51.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 4, 2023
First posted
Jan 12, 2023
StartActual
Sep 6, 2023
Primary completionActual
Oct 18, 2024
CompletionActual
Mar 17, 2025
Results first posted
Nov 10, 2025
Last update
Nov 10, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 10, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05682326
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Jan 12, 2023
Start date
Sep 6, 2023
Primary completion
Oct 18, 2024
Completion
Mar 17, 2025
Results posted
Nov 10, 2025
Last update
Nov 10, 2025

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: GSK1278863

Start the discussion